VRTX Stock Overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VRTX from our risk checks.
Narratives
BetaNarratives bring a range of perspectives from our community.
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$397.36 |
| 52 Week High | US$448.40 |
| 52 Week Low | US$316.43 |
| Beta | 0.37 |
| 1 Month Change | -2.53% |
| 3 Month Change | -9.17% |
| 1 Year Change | 21.24% |
| 3 Year Change | 81.29% |
| 5 Year Change | 135.79% |
| Change since IPO | 8,730.22% |
Recent News & Updates
Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05
Recent updates
Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued
Apr 30With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Apr 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued
Jan 23If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jan 02Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?
Oct 24Vertex to advance two AAT correctors to potentially treat rare, genetic disease
Oct 11Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?
Oct 02Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate
Sep 28Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook
Sep 19Vertex wins FDA label expansion for cystic fibrosis drug to add younger children
Sep 02Shareholder Returns
| VRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.7% | -3.9% | -3.1% |
| 1Y | 21.2% | -1.8% | 20.9% |
Return vs Industry: VRTX exceeded the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: VRTX underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| VRTX volatility | |
|---|---|
| VRTX Average Weekly Movement | 2.7% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VRTX has not had significant price volatility in the past 3 months.
Volatility Over Time: VRTX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 5,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
| VRTX fundamental statistics | |
|---|---|
| Market cap | US$102.49b |
| Earnings (TTM) | US$3.62b |
| Revenue (TTM) | US$9.87b |
28.4x
P/E Ratio10.4x
P/S RatioIs VRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRTX income statement (TTM) | |
|---|---|
| Revenue | US$9.87b |
| Cost of Revenue | US$4.43b |
| Gross Profit | US$5.44b |
| Other Expenses | US$1.82b |
| Earnings | US$3.62b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | 14.00 |
| Gross Margin | 55.16% |
| Net Profit Margin | 36.68% |
| Debt/Equity Ratio | 0% |
How did VRTX perform over the long term?
See historical performance and comparison